 |
VaxGen Phase III Vaccine Trial |
       |
Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials
Source:
AIDS 2003; 17(2):147-156
Authors:
Donald P. Francis; William L. Heyward; Vladimir Popovic; Patti
Orozco-Cronin; Karin Orelind; Carolyn Gee; Adrian Hirsch; Tina Ippolito;
Aimee Luck; Michael Longhi; Vineeta Gulati; Nathan Winslow; Marc Gurwith;
Faruk Sinangil; Phillip W. Berman
Abstract:
The world's first HIV vaccine efficacy trials will conclude in 2003.
Vaccines are developed and manufactured by industry. However, this task
cannot be accomplished by industry alone. To achieve the goal of providing
a safe and effective HIV vaccine for those in need, industry,
investors/funders, clinical and research partners-a collaboration of both
public and private institutions are needed. VaxGen Inc., as the industry
partner in this multi-partner collaboration, has learned many valuable
lessons that can be applied in the future to support the successful
development of an HIV vaccine. The results of the two efficacy trials of
candidate HIV-1 vaccines will be available during 2003. The first, the
AIDSVAX B/B trial, was started in 1998 in the USA, Canada, Puerto Rico and
the Netherlands. This trial concluded in late 2002 and initial efficacy
results were recently made available. The second, the AIDSVAX B/E trial,
was started in Bangkok, Thailand in 1999 and will similarly have initial
efficacy results available in late 2003. This paper reviewed the lessons
that have been learned through the experience of conducting the first
phase III HIV vaccine efficacy trials.
|
| | |